1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. North Carolina >
  6. Genexine Acquires Argos Therapeutics

M&A Deal Summary

Genexine Acquires Argos Therapeutics

On February 13, 2019, Genexine acquired life science company Argos Therapeutics for 11M USD

Acquisition Highlights
  • This is Genexine’s 1st transaction in the Life Science sector.
  • This is Genexine’s largest (disclosed) transaction.
  • This is Genexine’s 1st transaction in the United States.
  • This is Genexine’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2019-02-13
Target Argos Therapeutics
Sector Life Science
Buyer(s) Genexine
Deal Type Add-on Acquisition
Deal Value 11M USD

Target

Argos Therapeutics

Durham, North Carolina, United States
Argos Therapeutics, Inc. is a developer of therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Argos Therapeutics, Inc. was formed in 1997 and is headquartered in Durham, North Carolina.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Genexine

Seoul, South Korea
Category Company
Founded 1999
Sector Life Science
Employees86
Revenue 2.9B KRW (2024)
DESCRIPTION

Genexine is a clinical-stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next-generation novel long-acting biologics. Genexine was founded in 1999 and is based in Seoul, South Korea.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: North Carolina M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal